ANIP Q3 2023 Earnings — ANI Pharmaceuticals, Inc. Revenue & Financial Results | Market Cap Arena

ANIPANI Pharmaceuticals, Inc.

$2B

Q3 2023 Earnings

Healthcare Drug Manufacturers - Specialty & Generic

Income Statement

Revenue

$132M+57.3% YoY

Gross Profit

$84M63.5% margin

Operating Income

$18M13.6% margin

Net Income

$10M7.5% margin

EPS (Diluted)

$0.50

QoQ Revenue Growth

+13.1%

Cash Flow

Operating Cash Flow

$32M

Free Cash Flow

$28M

Stock-Based Comp.

$5M

Balance Sheet

Total Assets

$890M

Total Liabilities

$435M

Stockholders' Equity

$455M

Cash & Equivalents

$193M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$132M	$84M	+57.3%
Gross Profit	$84M	$51M	+64.4%
Operating Income	$18M	-$5M	+459.3%
Net Income	$10M	-$9M	+215.6%

Revenue Segments

Generics, Established Brands, and Other

$102M77%

Rare Disease

$30M23%

Geographic Segments

UNITED STATES

$132M100%